Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01749956 · ClinicalTrials.gov registry record · Phase 2
5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
A Phase 2 study of Rectal Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 11
- Study locations
NCT01749956 is a Phase 2 study of Rectal Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 39 participants, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The trial reports 11 study locations across 7 states.
The verdict
NCT01749956, a Phase 2 study of Rectal Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this Phase II study will be to investigate the antiangiogenic agent, aflibercept, in combination with chemoradiation as preoperative treatment for patients with stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus aflibercept adjuvantly.
Conditions Studied
Interventions
- RADIATION Radiation
- PROCEDURE Surgery
- DRUG Aflibercept
- DRUG FOLFOX6
Study Locations (11)
Florida
- Florida Cancer Specialists - Fort Myers
- Woodlands Medical Specialists - Pensacola
- Florida Cancer Specialists - St. Petersburg
- Space Coast Cancer Center - Titusville
Tennessee
- Tennessee Oncology - Chattanooga - Chattanooga
- Tennessee Oncology, PLLC - Nashville
Kentucky
- Baptist Hospital East - Louisville
Ohio
- Oncology Hematology Care, Inc. - Cincinnati
Oklahoma
- Oklahoma University - Oklahoma City
South Carolina
- South Carolina Oncology Associates - Columbia
Virginia
- Virginia Cancer Institute - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01749956
The ClinicalTrials.gov registry entry for NCT01749956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,166-participant average among 70 other Rectal Cancer trials with a reported enrollment target (99% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Radiation is the first listed.
NCT01749956 reports 11 study locations spanning 7 distinct geographic areas - top geographies include Florida, Tennessee, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01749956 about?
NCT01749956 is a clinical study titled "5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer". The purpose of this Phase II study will be to investigate the antiangiogenic agent, aflibercept, in combination with chemoradiation as preoperative treatment for patients with stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus aflibercept adjuvantly.
What is the current status of trial NCT01749956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2013-01. Estimated completion is 2015-09.
What conditions does trial NCT01749956 study?
This clinical trial studies the following conditions: Rectal Cancer.
What interventions are being tested in trial NCT01749956?
The interventions under investigation include: Radiation (RADIATION), Surgery (PROCEDURE), Aflibercept (DRUG), FOLFOX6 (DRUG).
Who is sponsoring clinical trial NCT01749956?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01749956 being conducted?
This trial has 11 study locations across Florida, Kentucky, Ohio, Oklahoma, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
RECRUITING · Phase 2
-
Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001
RECRUITING · Phase 2
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
RECRUITING · Phase 2
-
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.